Professor, Medicine-Hematology, University of Tennessee Health Science Center College of Medicine
Hematology
Dr. Harvey B. Niell, MD
|
|
Give Review
Harvey Niell works in the field of Hematology. He went to medical school at University of Tennessee College of Medicine. Harvey B. Niell has written publications. He has 59 publications published with PubMed. The lastest paper is: 'Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer.'
Publications
- Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).
- Diagnosis of Lung Cancer: A Bronchoscopist's Perspective.
- A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ???70 Years) with Stage IIIB/IV ...
- Differences in clinical trial patient attributes and outcomes according to enrollment setting.
- The impact of dose per cycle of etoposide and cisplatin on outcomes in patients with extensive small-cell lung Cancer.
- Therapy-related acute myeloblastic Leukemia after mitoxantrone treatment in a patient with MS.
- Treatment outcomes of different prognostic groups of patients on Cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared...
- Small cell lung Cancer clinical practice guidelines in oncology.
- Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B.
- Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage ...
- End-of-life care in patients with lung Cancer.
- Taxol and taxotere in bladder Cancer: in vitro activity and urine stability.
- Cytotoxic effects of alpha- and gamma-interferon and tumor necrosis factor in human bladder tumor cell lines.
- Phase II study of prolonged oral etoposide in combination with intravenous cisplatin in advanced non-small cell lung Cancer.
- Free-riding and the prisoner's dilemma: problems in funding economic Analyses of phase III cancer clinical trials.
- Postabsorptive urinary hydroxyproline test in patients with metastatic bone disease from breast Cancer.
- The postabsorptive urinary hydroxyproline (spot-HYPRO) in patients with multiple Myeloma.
- Time- and concentration-dependent inhibition of the clonogenic growth of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced murine bladder tumor cell lines by cis-di...
- In vitro characterization of four N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) induced mouse bladder tumors.
- The clonogenic growth of cells derived from bladder barbotage in patients with transitional cell carcinoma of the bladder: a preliminary report.
- Growth characteristics of N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT)-induced mouse bladder tumor lines in a human tumor stem cell assay.
- The use of a tumor colony assay in predicting chemotherapeutic drug response in murine bladder Cancer.
- Chemotherapy of murine bladder Cancer: in vitro and in vivo.
- Total and nondialyzable hydroxyproline excretion in Stage D2 prostate Cancer.
- Use of tumor colony assay in clinical oncology.
- Total, dialyzable, and nondialyzable postabsorptive hydroxyproline. Values in patients with Cancer.
- The postabsorptive hydroxyproline in the long-term evaluation of patients with breast Cancer.
- Incidence of Pneumocystis carinii antigenemia in ambulatory Cancer patients.
- Systemic chemotherapy of murine bladder Cancer.
- Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the Lung.
- Reversed-phase high-performance liquid chromatographic determination of mitomycin C in human serum.
- Use of the tumour colony assay in the evaluation of patients with bladder Cancer.
- Pneumocystis carinii antigenemia in adults with malignancy, infection, or pulmonary Disease.
- Combination chemotherapy with mitomycin C, methotrexate, cisplatin, and vinblastine in the treatment of non-small cell lung Cancer.
- Pneumonia and Hong Kong influenza: a prospective study of the 1968-1969 epidemic.
- AntiCancer drug activity in human bladder tumor cell lines.
- Combination chemotherapy with mitomycin-C, cisplatin, and vinblastine in the treatment of non-small-cell lung Cancer.
- In vitro and in vivo activity of two second generation platinum Analogs in murine bladder cancer.
- Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines.
- Skeletal surveys in multiple Myeloma. Radiologic-clinical correlation.
- Detection of small cell lung Cancer bone marrow involvement by discontinuous gradient sedimentation.
- Evidence for depressed humoral immunity to Pneumocystis carinii in homosexual males, commercial plasma donors, and patients with acquired immunodeficiency Syndrome.
- Effect of concentration and time of drug exposure on clonal growth of murine bladder Cancer.
- 5-Fluorouracil infusion and mitomycin combination chemotherapy in the management of patients with advanced non-small-cell lung Cancer.
- Combination versus sequential single-agent chemotherapy in the treatment of patients with advanced non-small cell lung Cancer.
- Clonal growth requirements of human bladder tumor cell lines.
- Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung Cancer.
- Miconazole carrier solution, hyperlipidemia and hematologie problems.
- Zinc metabolism in sickle cell Anemia.
- Extensive stage small cell lung Cancer.
- Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide.
- Efficacy of targeted chemoradiation and planned selective neck dissection to control bulky nodal disease in advanced head and neck Cancer.
- Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung Cancer.
- Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck Cancer: the Memphis experience.
- Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung Cancer.
- Carboplatin/etoposide/paclitaxel in the treatment of patients with extensive small-cell lung Cancer.
- Demyelination in the brain as a paraneoplastic disorder: candidates include some cases of Leukemia and non-Hodgkin''s lymphoma.
- A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung Cancer.
Schools
University of Tennessee Memphis College of Medicine amp Surgery
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- Breast Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Tennessee -
University of Southern California - LAC+USC Medical Center -
University of Tennessee College of Medicine
Hospital
-
University of Tennessee Medical Center
Helpful Reviews
Similar Doctors
|
Dr. Edward S. Muir, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Moon J. Fenton, MD |
|
|
Dr. G G. Tian, MD |
|
|
Dr. Arthur W. Nienhuis, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Peter W. Carter, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Norman I. Heching, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barry Boston, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John K. Choi, MD |
|
|
Dr. Andrew E. Fintel, DO |
|
|
Dr. David M. Stern, MD |
|
|
Dr. Michelle T. Chi, MD |